Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

B. Zaric



Author of

  • +

    P1.02 - Biology/Pathology (ID 614)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Biology/Pathology
    • Presentations: 1
    • +

      P1.02-007 - TP53 and DNA-Repair Gene Polymorphisms as Risk Factors for the Development of Advanced Lung Adenocarcinoma in Serbia (ID 9060)

      09:30 - 09:30  |  Author(s): B. Zaric

      • Abstract

      Background:
      TP53 and DNA repair genes polymorphisms have been proposed as clinically significant cancer risk factors. The TP53 gene, coding for a known tumor suppressor, is found to be mutated in over 30% of human cancers. Impaired DNA repair efficiency caused by differences in expression, methylation and polymorphisms of DNA repair genes XRCC1 and Rad51 is likely to affect cancer occurence. This study aimed to evaluate the association of the TP53 Arg72Pro single-nucleotide polymorphism (SNP) (rs1042522), XRCC1 Arg399Gln SNP (rs25487) and Rad51 G135C SNP (rs1801320) with the occurrence of lung adenocarcinoma in Serbia, both individually and in combination.

      Method:
      This case-control study included 65 advanced lung adenocarcinoma patients treated at two Institutes in Serbia, stage IIIB or IV, and ECOG performance status 0, 1 or 2, and 68 healthy matched controls. All subjects were of Caucasian descent. TP53, XRCC1 and Rad51 genotyping was done by polymerase chain reaction followed by restriction length polymorphism (PCR-RFLP). Statistical analysis was performed using the Chi-square test and descriptive analyses included genotype and allelic frequencies. Deviations of the genotype frequencies from those expected under Hardy-Weinberg equilibrium were assessed using the χ2 test. The odds ratio (OR) and 95 % confidence intervals (CI) were also calculated as an estimate of relative risk, with significance set at p < 0.05 for all analyses.

      Result:
      The frequencies of XRCC1 alleles in patients vs. controls were 0.75 vs. 0.6 for Arg, and 0.25 vs. 0.4 for Gln. XRCC1 Arg allele was significantly associated with the development of lung adenocarcinoma only in the recessive model [p=0.019; OR (95% CI) = 2.47 (1.21 - 5.05)]. The frequencies of Rad51 alleles in patients vs. controls were 0.78 vs. 0.76 for G, and 0.22 vs. 0.24 for C. The frequencies of TP53 alleles in patients vs. controls were 0.52 vs. 0.63 for Arg, and 0.48 vs. 0.37 for Pro. We found no statistically significant associations of Rad51 and TP53 polymorphisms with lung adenocarcinoma. Investigating all possible gene-gene interactions, we also found no statistically significant associations with lung adenocarcinoma.

      Conclusion:
      In this study, homozygous carriers of the XRCC1 Arg allele were found to be more susceptible to the development of lung adenocarcinoma during lifetime. Thus, XRCC1 genotyping might be useful as an additional tool for predicting individual lung cancer risk

  • +

    P2.10 - Nursing/Palliative Care/Ethics (ID 711)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Nursing/Palliative Care/Ethics
    • Presentations: 1
    • +

      P2.10-005 - Overall Survival of Lung Cancer Patients with Brain Metastases in a Developing Country (ID 9611)

      09:30 - 09:30  |  Author(s): B. Zaric

      • Abstract

      Background:
      Brain metastases (BM) are common in due course of lung cancer (LC). The clinical presentation of BM can be very distressing for family/caregivers and urges for immediate treatment. Despite the early diagnosis and multimodality treatment of BM, prognosis remains poor. Considering the fact that treatment options in developing countries are limited (WBRT, surgery and SBRT) individual approach and specific prognostic assessment is highly important for further disease management. Aim of this study was to gather information and make approximation of overall survival (OS) of LC patients with BM.

      Method:
      This observational trial was conducted at the Institute for Pulmonary Diseases of Vojvodina, Serbia in the period from March 2010 to April 2015 taking into account all newly diagnosed LC patients. All data were harvested from the hospital based data capture system. The survival estimations were calculated regardless of the therapeutic interventions applied. Median OS was determined via Kaplan-Meier curves for all subgroups of LC patients with BM.

      Result:
      BM were diagnosed in 336 (5.1%) out of 6.624 LC patients in this 5 year period. Out of them, 182 patients were eligible for evaluation in this trial, the rest were excluded due to missing data. Majority of patients were male 68.1% (124), older than 60 years 50.0% (91), smokers 73.6% (134) with ECOG PS 1 76.4% (139). Most frequent LC type was adenocarcinoma 59.3% (108) followed by small-cell, squamous cell, and other types; 19.2% (35), 13.2% (24) and 8.2% respectively (13). One BM was present in 63.0% (63), 2-3 BM in 52.0% (52) and more than 3 in 34.6% (63) of patients. Extra cranial metastases (ECM) were present in 60.4% (110) of patients Median OS of all patients with BM regardless the histology was 8.5 (95%CI: 7.8-12.2) months. Median OS of patients with NSCLC, SCLC and other tumour types was 8.5 months (95%CI: 6.0-10.9), 10.0 months (95%CI: 7.8-12.2), and 5.5 months (95%CI: 0.1-11.0) respectively. Lowest median survival period was observed in patients with ECOG PS >3; 3.60 (95%CI: 0.2-7.0) months.

      Conclusion:
      The survival results of this trial show consistency with historical survival times. These results may suggest that survival outcomes for LC patients with BM are independent of applied therapy. Approximate survival prognosis taking into consideration individual (age and ECOG) and objective (tumour type, number of BM and presence of ECM) patient characteristics is highly important for further disease management in order to decrease patients burden and increase cooperation with family/caregivers.